Clinical trials: Fetal Hemoglobin
Sickle Cell Disease, Chronic Kidney Disease
Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia
This study will examine the use of hydroxyurea and erythropoietin for treating sickle cell disease in patients who also have kidney disease or pulmonary hypertension (high blood pressure in the lungs).
- Conditions
- Sickle Cell Disease, Chronic Kidney Disease, Pulmonary Hypertension
- Trial name
- NCT00270478
- Testing
- Erythropoietin and Hydroxyurea
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hemoglobin SC Disease, Sickle Cell Anemia
A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders
Sickle cell anemia is a genetic disorder that results from a single nucleotide substitution in codon 6 of the beta-globin gene which, in the homozygous state, produces an abnormal hemoglobin that is prone to polymer formation…
- Trial name
- NCT00005783
- Testing
- Recombinant-methionyl human stem cell factor
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Extremely Premature Infant, Anemia Neonatal
Heterologous Cord Blood-Derived Red Blood Cell for Transfusion in Extremely Preterm Infants
Anemia is a condition in which there are not enough red blood cells to carry oxygen throughout the body. It is very common in extremely preterm infants (born before 28 weeks of pregnancy), and many of these babies require red…
- Conditions
- Extremely Premature Infant, Anemia Neonatal, Blood Transfusion, Umbilical Cord Blood
- Trial name
- NCT07502781
- Testing
- Cord Blood Red Blood Cells, Standard Adult Donor Red Blood Cells
- Where
- Spain
- Volunteers
- 176 people
- Sponsor
- Hospital Clinic of Barcelona
Beta-Thalassemia
Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients (THALA-RAP)
In β-thalassaemia and Sickle Cell Disease (SCD), a significant production of fetal haemoglobin (HbF) may reduce the severity of clinical course and reactivation of γ-globin gene expression in adulthood.
- Trial name
- THALA-RAP (NCT04247750)
- Testing
- Sirolimus 0.5 mg
- Where
- 4 sites in Italy
- Volunteers
- 45 people
- Sponsor
- Università degli Studi di Ferrara
Stunting, Maternal-Fetal Relations
Family-based Health Education Program and Zinc Supplementation for Stunted Mother
Background : It is important to tackle the issue of malnutrition at an early stage. A stunted mother has a tendency of having adverse neonatal outcomes including growth restriction.
- Trial name
- NCT05100550
- Testing
- Zinc, Control
- Where
- Indonesia
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Hasanuddin University
Sickle Cell Disease, Sickle Cell Anemia
Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease
Sickle Cell Disease (SCD) is a hereditary anemia that causes the red blood cells to change their shape from a round and doughnut-like shape to a half-moon/crescent, or sickled shape.
- Trial name
- NCT01000155
- Testing
- vorinostat
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute
Anemia in Pregnancy, Pre-eclampsia
A Retrospective Analysis of Neevo® and NeevoDHA® Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy
This study is a multi-site, retrospective chart review to determine the effect of Neevo® or NeevoDHA® (with higher folate and B12) versus standard prenatal vitamins on hemoglobin (Hgb) levels in pregnant women throughout the…
- Trial name
- NCT01193192
- Testing
- Neevo®, Prenatal vitamins
- Where
- 3 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pamlab, L.L.C.
Sickle Cell Anemia
Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia
A total of fifty severely affected patients with homozygous sickle cell disease or other sickling disorders (e.g. B negative or B positive Thalassemia/Sickle) who are greater than 18 years of age will be eligible for treatment.
- Trial name
- NCT00001197
- Testing
- Hydroxyurea
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Beta-Thalassemia
Comparison Of Efficacy And Safety Of Thalidomide Vs Hydroxyurea In Thalassemia Patients: A Single-Centre Pilot Study.
The goal of this study is to compare the effectiveness and safety of two hemoglobin F inducer. This is single centered interventional pilot study is to compare the efficacy and safety parameters in beta thalassemia patients.
- Trial name
- NCT06239389
- Testing
- Thalidomide 100mg, Hydroxyurea
- Where
- Pakistan
- Volunteers
- 24 people
- Sponsor
- National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Fetal Growth Restriction, Small for Gestational Age at Delivery
Evaluation of HALP Score in Distinction Between FGR and SGA
Fetal Growth Restriction (FGR) and Small for Gestational Age (SGA) are two conditions that can happen when a baby doesn't grow as much as expected during pregnancy.
- Trial name
- NCT05814198
- Testing
- HALP score
- Where
- Turkey (Türkiye)
- Volunteers
- 400 people
- Sponsor
- Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Pregnancy, Helicobacter Pylori Infection
Effects of Dietary Heme/Non-heme Iron and Helicobacter Pylori (Hp) Infection on Maternal Iron-deficiency Anemia and Fetal Growth Outcomes
Iron deficiency is considered one of the main nutritional deficiency disorders despite the apparent availability of a high-quality diet even in developed countries, and Iron deficiency anemia (IDA) is the most common form of…
- Conditions
- Pregnancy, Helicobacter Pylori Infection, Iron-Deficiency Anemia
- Trial name
- NCT01071759
- Where
- Taiwan
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- E-DA Hospital